BMRN Research and Charts

BMRN - Biomarin Pharmaceutical Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2026-01-25 (Delayed quote data 2026-02-10)

Last 59.66	Change ⇑ +1.85 (+3.20%)	Volume 3,329,734
	Open 57.90	High 60.73	Low 57.90

8EMA (Daily) 57.98	40EMA (Daily) 57.02	50EMA (Daily) 56.81	STO (Daily) 76.339	MACD Hist (Daily) 0.301
8EMA (Weekly) 57.620	40EMA (Weekly) 58.17	50EMA (Weekly) 59.34	STO (Weekly) 47.653	MACD Hist (Weekly) 0.352


Company Profile
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.